|
NOVEN
EXPECTS SECOND QUARTER EARNINGS |
Back Miami, FL, July 2,
2002 – Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced
that, based on a preliminary review of its financial results for the June
30 quarter, it expects to exceed its prior public earnings guidance for
the second quarter of $0.14 to $0.17 per share.
"We had forecast
a strong second quarter, and we now expect that earnings will be even
better than our most recent guidance," said Robert C. Strauss, Noven's
President, CEO & Chairman. "We plan to announce second quarter financial
results on or about August 1, and expect to update our full-year guidance
at that time."
This release contains forward-looking statements related to the business of Noven that can be identified by the use of forward-looking terminology such as "expects" and "plans" and similar words and phrases. Such statements are qualified by and subject to the risks and uncertainties specified in Noven's most recent filings with the Securities and Exchange Commission and in this press release, including the risk that actual second quarter results may not exceed Noven's most recent public guidance because of issues identified in Noven's and its independent accountant's review of the second quarter financial results, including potential GAAP adjustments that may negatively impact earnings.
Investor
& Media Contact:
Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
(305) 253-1916
Copyright © 2002 Noven Pharmaceuticals, Inc. All rights reserved.